Email this article 7-Methylguanine Inhibits Colon Cancer Growth in vivo
- Authors: Kirsanov K.I.1,2, Fetisov T.I.1, Antoshina E.E.1, Gor’kova T.G.1, Trukhanova L.S.1, Shram S.I.3, Nagaev I.Y.3, Zolotarev Y.A.3, Abo Qoura L.1,2, Pokrovsky V.S.1,2, Yakubovskaya M.G.1, Švedas V.K.4, Nilov D.K.4
-
Affiliations:
- Blokhin National Medical Research Center of Oncology
- RUDN University
- National Research Centre “Kurchatov Institute”
- Lomonosov Moscow State University
- Issue: Vol 16, No 2 (2024)
- Pages: 50-52
- Section: Research Articles
- Submitted: 08.05.2024
- Accepted: 26.06.2024
- Published: 21.08.2024
- URL: https://actanaturae.ru/2075-8251/article/view/27422
- DOI: https://doi.org/10.32607/actanaturae.27422
- ID: 27422
Cite item
Abstract
7-Methylguanine (7-MG) is a natural inhibitor of poly(ADP-ribose) polymerase 1 and tRNA-guanine transglycosylase, the enzymatic activity of which is central for the proliferation of cancer cells. Recently, a number of preclinical tests have demonstrated the safety of 7-MG and a regimen of intragastric administration was established in mice. In the present work, the pharmacological activity of 7-MG was studied in BALB/c and BALB/c nude mice with transplanted tumors. It was found that 7-MG effectively penetrates tumor tissue and suppresses colon adenocarcinoma growth in the Akatol model, as well as in a xenograft model with human HCT116 cells.
About the authors
K. I. Kirsanov
Blokhin National Medical Research Center of Oncology; RUDN University
Email: nilovdm@gmail.com
Institute of Carcinogenesis; Medical Institute
Russian Federation, Moscow, 115478; Moscow, 117198T. I. Fetisov
Blokhin National Medical Research Center of Oncology
Email: nilovdm@gmail.com
Institute of Carcinogenesis
Russian Federation, Moscow, 115478E. E. Antoshina
Blokhin National Medical Research Center of Oncology
Email: nilovdm@gmail.com
Institute of Carcinogenesis
Russian Federation, Moscow, 115478T. G. Gor’kova
Blokhin National Medical Research Center of Oncology
Email: nilovdm@gmail.com
Institute of Carcinogenesis
Russian Federation, Moscow, 115478L. S. Trukhanova
Blokhin National Medical Research Center of Oncology
Email: nilovdm@gmail.com
Institute of Carcinogenesis
Russian Federation, Moscow, 115478S. I. Shram
National Research Centre “Kurchatov Institute”
Email: nilovdm@gmail.com
Russian Federation, Moscow, 123182
I. Yu. Nagaev
National Research Centre “Kurchatov Institute”
Email: nilovdm@gmail.com
Russian Federation, Moscow, 123182
Yu. A. Zolotarev
National Research Centre “Kurchatov Institute”
Email: nilovdm@gmail.com
Russian Federation, Moscow, 123182
L. Abo Qoura
Blokhin National Medical Research Center of Oncology; RUDN University
Email: nilovdm@gmail.com
Institute of Carcinogenesis; Medical Institute
Russian Federation, Moscow, 115478; Moscow, 117198V. S. Pokrovsky
Blokhin National Medical Research Center of Oncology; RUDN University
Email: nilovdm@gmail.com
Institute of Carcinogenesis; Medical Institute
Russian Federation, Moscow, 115478; Moscow, 117198M. G. Yakubovskaya
Blokhin National Medical Research Center of Oncology
Email: nilovdm@gmail.com
Institute of Carcinogenesis
Russian Federation, Moscow, 115478V. K. Švedas
Lomonosov Moscow State University
Email: nilovdm@gmail.com
Belozersky Institute of Physicochemical Biology; Faculty of Bioengineering and Bioinformatics
Russian Federation, Moscow, 119991D. K. Nilov
Lomonosov Moscow State University
Author for correspondence.
Email: nilovdm@gmail.com
Belozersky Institute of Physicochemical Biology
Russian Federation, Moscow, 119991References
- Topp H., Sander G., Heller-Schöch G., Schöch G. // Anal. Biochem. 1987. V. 161. P. 49–56.
- Nilov D.K., Tararov V.I., Kulikov A.V., Zakharenko A.L., Gushchina I.V., Mikhailov S.N., Lavrik O.I., Švedas V.K. // Acta Naturae. 2016. V. 8. № 2. P. 108–115.
- Nilov D., Maluchenko N., Kurgina T., Pushkarev S., Lys A., Kutuzov M., Gerasimova N., Feofanov A., Švedas V., Lavrik O., et al. // Int. J. Mol. Sci. 2020. V. 21. P. 2159.
- Kurgina T.A., Shram S.I., Kutuzov M.M., Abramova T.V., Shcherbakova T.A., Maltseva E.A., Poroikov V.V., Lavrik O.I., Švedas V.K., Nilov D.K. // Biochemistry (Mosc.). 2022. V. 87. P. 823–831.
- Shram S.I., Shcherbakova T.A., Abramova T.V., Baradieva E.C., Efremova A.S., Smirnovskaya M.S., Silnikov V.N., Švedas V.K., Nilov D.K. // Biochemistry (Mosc.). 2023. V. 88. P. 783–791.
- Pushkarev S.V., Vinnik V.A., Shapovalova I.V., Švedas V.K., Nilov D.K. // Biochemistry (Mosc.). 2022. V. 87. P. 443–449.
- Zhang J., Lu R., Zhang Y., Matuszek Ż., Zhang W., Xia Y., Pan T., Sun J. // Cancers (Basel). 2020. V. 12. P. 628.
- Ohmoto A., Yachida S. // Onco Targets Ther. 2017. V. 10. P. 5195–5208.
- Mittica G., Ghisoni E., Giannone G., Genta S., Aglietta M., Sapino A., Valabrega G. // Recent Pat. Anticancer Drug Discov. 2018. V. 13. P. 392–410.
- Kirsanov K., Fetisov T., Antoshina E., Trukhanova L., Gor’kova T., Vlasova O., Khitrovo I., Lesovaya E., Kulbachevskaya N., Shcherbakova T., et al. // Front. Pharmacol. 2022. V. 13. P. 842316.
- Fetisov T.I., Tilova L.R., Lesovaya E.A., Antoshina E.E., Gor’kova T.G., Trukhanova L.S., Morozova O.V., Shipaeva E.V., Ivanov R.V., Purmal A.A., et al. // Adv. Mol. Oncol. 2016. V. 3. P. 67–72.
- Zolotarev Y.A., Dadayan A.K., Borisov Y.A., Kozik V.S. // Chem. Rev. 2010. V. 110. P. 5425–5446.
Supplementary files
